Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2019

View Archived Issues

Preclinical characterization of the novel covalent Inhibitor of CDK7, SY-1365

Checkpoint blockade protects from homeostatic inhibition and amplifies antitumor T-cell responses

POU3F3 disruptions linked to neurodevelopmental disorder

Panitumumab-IRDye800 in phase II for metastatic lymph node identification in HNSCC

First preclinical data presented on miR-132 inhibitor CDR132L in heart failure model

Alcohol consumption is deceased with FGFR1 inhibition in rodents

Lower affinity means lower affinity, but higher persistence, for CAR T cells

Eicosis' soluble epoxide hydrolase inhibitor EC-5026 to enter the clinic

UCn2 gene transfer improves diabetes-related left-ventricular dysfunction in mice

KBP Biosciences patents new bacterial LpxC inhibitors

HIV rebound shows diverse sources, identical virus

Daiichi Sankyo presents new analgesics

TREM2 correlates with slow decline in AD

Crinetics Pharmaceuticals identifies somatostatin SST5 receptor agonists

Eli Lilly and Company describes PDE1 inhibitors

eXIthera Pharmaceuticals divulges coagulation factor XIa and kallikrein inhibitors

Suven evaluates SUVN-G3031 in phase II trial for narcolepsy with and without cataplexy

ObsEva reports mechanism-of-action data on oxytocin receptor antagonist nolasiban

FDA approves Kuros' IND for phase IIa trial of KUR-113 for spinal fusion

Twinrab approved in India for rabies

Grunenthal and UniQuest establish neuropathic pain collaboration

Boehringer Ingelheim to advance BI-456906 into phase II for obesity and diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...